Level Up Your IVL Skills with Calcium Crush! We're thrilled to unveil the latest addition to Cardio Ex — Calcium Crush. A collaboration of Level Ex + Shockwave Medical, this game offers cardiologists a captivating way to explore calcium morphologies, understand pulse management techniques, and advance #ShockwaveIVL strategies — all while using the new #ShockwaveC2plus technology. Show us how you shock! Start playing here. iOS: https://lnkd.in/gGKuy_P3 Android: https://lnkd.in/gvu7EzH2 US Rx only. Important Safety Information: http://bit.ly/3iEq7fC
Shockwave Medical
Herstellung medizinischer Geräte
Santa Clara, California 83,585 followers
Making waves for underserved patients with cardiovascular disease via novel technologies. ⚡🌊
Über uns
Shockwave Medical is revolutionizing the interventional treatment of advanced cardiovascular disease by developing technology that targets calcified plaque. Inspired by 30-years of safety and efficacy in kidney stone treatment, our Intravascular Lithotripsy family of catheters delivers localized lithotripsy at the site of cardiovascular calcium that enables gentle balloon dilatation of calcified, stenotic arteries. IVL catheters use sonic pressure waves to preferentially impact hard tissue, disrupting calcium, while leaving soft tissue undisturbed. An integrated balloon catheter then dilates the calcified lesion at low-pressure, restoring blood flow. Stay connected with us at www.ShockwaveMedical.com and on Twitter @ShockwaveIVL
- Website
-
http://shockwavemedical.com
External link for Shockwave Medical
- Industrie
- Herstellung medizinischer Geräte
- Größe des Unternehmens
- 1.001-5.000 Mitarbeiter
- Hauptsitz
- Santa Clara, California
- Typ
- Öffentliches Unternehmen
Standorte
-
Primäre
5403 Betsy Ross Dr
Santa Clara, California 95054, US
Employees at Shockwave Medical
-
Lori Dossola Lyle
Marketing at Shockwave Medical, Inc.
-
Erika Johnson
-
Bharath Natarajan
Senior Director, Data Platform and Business Intelligence
-
Jason Shields
Medical Device Executive | General Management | Commercial Execution | Marketing | Professional Education | Business Development | Digital Surgery
Aktualisierungen
-
International physicians, curious about the mounting clinical evidence supporting the #ShockwaveReducer’s safety and efficacy when treating patients suffering from refractory angina? Watch Prof Stefan Verheye’s presentation from #EuroPCR 2024 to get a summary of the data published: https://lnkd.in/dtEMB6u2 Want to watch more clips from the PCR 2024 Reducer Symposium? Visit our updated website: https://lnkd.in/g7-UqNsF ISI http://bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
-
-
With the larger diameter sizes of #ShockwaveL6 ranging from 8.0mm to 12.0mm, Dr Shivani Kumar explains how Shockwave L6 helps her safely and effectively treat heavily calcified iliac arteries. Watch here: https://lnkd.in/gb_7ki9p US Rx only. Important Safety Information: http://bit.ly/3iEq7fC #ShockwaveIVL
-
-
Congratulations to Dr Prashanth Raju and the whole team at Kettering General Hospital NHS Foundation Trust in Northamptonshire, UK for a successful start to their Reducer program. International physicians, check out the inspirational story featured in BBC News of their patient suffering from debilitating Refractory Angina who is now able to enjoy his life again thanks to a successful #ShockwaveReducer implantation. Read the BBC article here: https://lnkd.in/etXKjXia ISI http://bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
-
-
In the CathPCI Registry Post-Approval Study, the observed mortality rate was in-line with the predicted rate when treating coronary artery calcium in #ACS patients with #CoronaryIVL. Read Dr Dean Kereiakes’s takeaways in the Q&A: https://lnkd.in/gAVFKRFk US Rx only. Important Safety Information: http://bit.ly/3iEq7fC #ShockwaveIVL
-
-
The experts have spoken! 📣 Read the consensus statement from an international expert panel regarding #ShockwaveIVL use in the femoropopliteal segment. A huge thank you to Prof Athanasios Saratzis, Dr Sarah Jane Messeder, Dr Narayanan Thulasidasan et al. for developing this guidance. Read the open access article here: https://lnkd.in/gzfxKmkY US Rx only. Important Safety Information: http://bit.ly/3iEq7fC
-
-
In the latest interview & case review with Dr Shivani Kumar, she shares how #ShockwaveIVL can safely & effectively modify challenging calcium across the iliacs. With low pressure of 2-4atm and focused treatment, #ShockwaveL6 is purpose-built for the iliacs. Watch now: https://lnkd.in/gb_7ki9p US Rx only. Important Safety Information: http://bit.ly/3iEq7fC
-
-
Cheers to Dr Jason Wollmuth and his team at Providence Heart Clinic – St. Vincent in Portland, OR on their 1st randomized patient in the #COSIRAII trial! 🌲 To learn more about the COSIRA-II trial and for a list of participating sites visit www.clinicaltrials.gov ISI http://bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
-
-
We love to see it! Congratulations to Dr Matthew Summers, Dr Paul Lavigne, and the team at Sentara Health in Norfolk, VA on treating your 1st single arm patient in the COSIRA-II study. The right-side reversible ischemia single arm patient received #ShockwaveReducer with the goal of providing relief for their refractory angina. To learn more about the #COSIRAII trial and for a list of participating sites visit http://clinicaltrials.gov ISI http://bit.ly/3iEq7fC Caution: Investigational Device. Limited by U.S. and Canadian law to investigational use. The Reducer is commercially available in certain countries outside the U.S. and Canada. Please contact your local representative for specific country availability.
-
-
You don’t want to miss this...🔎 Read the new article published in JEVT featuring an international expert consensus approach to #ShockwaveIVL application in fempop disease. Read the open access article here: https://lnkd.in/gzfxKmkY US Rx only. Important Safety Information: http://bit.ly/3iEq7fC
-